Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer A Prospective Multiple-center Phase II Study
Latest Information Update: 06 Jun 2023
At a glance
- Drugs Eribulin (Primary) ; Tislelizumab (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms TEMPLATE
- 08 Jun 2021 New trial record